GeneReach Biotechnology Net Tangible Assets

GeneReach Biotechnology (4171.TWO) currently reports a net tangible assets of $580M as of June 2026. That compares with $620M in the prior-year period — down 6.9% year over year. Use the charts on this page to explore GeneReach Biotechnology's net tangible assets history and peer comparisons.

GeneReach Biotechnology's net tangible assets decreased from $620M to $580M — a 6.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GeneReach Biotechnology reported $580M in net tangible assets as of June 2026. That compares with $620M in the prior-year period — down 6.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $580M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GeneReach Biotechnology, and consider following 4171.TWO for alerts when major investors trade the stock.

GeneReach Biotechnology is classified in the Healthcare sector. On net tangible assets, it currently shows $580M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4171.TWO with unrelated industries.